Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications
AssigneeBen-Gurion University of the Negev Research and Development Authority
InventorsAyelet David, Gonen Ashkenasy, Yosi Shamay
Life of this patent
Estimating the term…
Abstract
The caged cell-penetrating peptide (cCPP) conjugates of this invention are ideal for intracellular delivery of a broad variety of cargoes including various nanoparticle pharmaceutical carriers (liposomes, micelles, microparticles, nanoparticles, polymer-conjugates). The conjugates comprise a detectable agent or a therapeutic agent, and the conjugates provide a novel strategy for site-specific delivery of the same to appropriate tissues in the subject. Versatile application of the conjugates in diagnostics and imaging is described.
Claims11
A method of imaging a cancerous cell or cancerous tissue or an inflamed tissue in a subject in need thereof, the method comprising:
- a) contacting the cancerous cell or cancerous tissue or contacting the inflamed tissue with a caged cell penetrating peptide (cCPP)-macromolecular carrier conjugate of formula 1:
- wherein
- x, y, u, and z are independently percentages of the respective element composition of the conjugate, wherein x is present from 0.05%-50%, y is present from 0-50%, u is present from 0-50% and z is present from 0-50%;
- P is a caged cell penetrating peptide, wherein the amino acid sequence of the cell penetrating peptide comprises the amino acid sequence KRRMKWKK;
- M is a macromolecular carrier molecule consisting of underivatized monomers selected from the group consisting of N-(2-hydroxypropyl)methacrylamide (HPMA), N-methylacrylamide, N,N-dialkylacrylamides, acrylic acid, polyethylene glycol, methacrylic acid, polyamino acids, polysaccharides, polyvinyl pyrrolidone-maleic anhydride polymers, polylactic-co-glycolic acid, and combinations thereof;
- D is a detectable agent or a therapeutic agent, or a combination thereof, wherein the detectable agent is fluorescent, radioactive, luminescent or electron dense, and wherein the therapeutic agent is a toxin, a chemotherapeutic agent, D(KLAKLAK)2, KLAK, a radioisotope, an antimetabolite, a microtubule inhibitor, or a combination thereof;
- and
- J and K are spacer molecules;
- b) uncaging the cCPP, wherein the conjugate is specifically internalized within the cancerous cell or cancerous tissue or inflamed tissue, or cells proximally located thereto;
- and
- c) imaging the cancerous cell and cancerous tissue or the inflamed tissue of the subject by detecting the uptake of the detectable agent D of the conjugate by the cancerous cell or cancerous tissue or by the inflamed tissue.
A method of treating a cancerous cell or cancerous tissue or an inflamed tissue in a subject in need thereof, the method comprising:
- a) contacting a cancerous tissue or cancerous tissue or the inflamed tissue of the subject in need thereof with an effective amount of a caged cell penetrating peptide (cCPP)-macromolecular carrier conjugate of formula 1:
- wherein
- x, y, u, and z are independently percentages of the respective element composition of the conjugate, wherein x is present from 0.05%-50%, y is present from 0-50%, u is present from 0-50% and z is present from 0-50%;
- P is a caged cell penetrating peptide, wherein the amino acid sequence of the cell penetrating peptide comprises the amino acid sequence KRRMKWKK;
- M is a macromolecular carrier molecule consisting of underivatized monomers selected from the group consisting of N-(2-hydroxypropyl)methacrylamide (HPMA), N-methylacrylamide, N,N-dialkylacrylamides, acrylic acid, polyethylene glycol, methacrylic acid, polyamino acids, polysaccharides, polyvinyl pyrrolidone-maleic anhydride polymers, polylactic-co-glycolic acid, and combinations thereof;
- D is a detectable agent or a therapeutic agent, or a combination thereof, wherein the detectable agent is fluorescent, radioactive, luminescent or electron dense, and wherein the therapeutic agent is a toxin, a chemotherapeutic agent, D(KLAKLAK)2, KLAK, a radioisotope, an antimetabolite, a microtubule inhibitor, or a combination thereof;
- and
- J and K are spacer molecules;
- b) uncaging the cCPP, wherein the conjugate is specifically internalized within the cancerous cell or cancerous tissue or inflamed tissue, or cells proximally located thereto;
- and
- c) delivering the therapeutic agent of step (a) inside the cancerous cell or cancerous tissue or inside the inflamed tissue of the subject in need thereof.
Dependencies are inferred from the claim text.